vTv Therapeutics IncNASDAQ:VTVT
- LAST PRICE26.9650
- TODAY'S CHANGE (%)1.1950 (4.6372%)
- Bid / Lots16.0400/ 1
- Ask / Lots30.0000/ 3
- Open / Previous Close26.5700 / 25.7700
- Day Range
- 52 Week Range
- Volume3,777
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VTVT |
|---|---|---|
| 12:25 ET | 100 | 26.57 |
| 02:58 ET | 100 | 25.62 |
| 03:20 ET | 200 | 26.312 |
| 03:25 ET | 100 | 25.77 |
| 03:54 ET | 100 | 26.965 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
vTv Therapeutics Inc | 77.6M | -2.8x | --- |
Tempest Therapeutics Inc | 77.2M | -1.8x | --- |
CEL-SCI Corp | 78.3M | -2.1x | --- |
Cognition Therapeutics Inc | 75.3M | -2.3x | --- |
Passage Bio Inc | 75.2M | -0.7x | --- |
Connect Biopharma Holdings Ltd | 74.9M | -1.2x | --- |
Company Information
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.
Contact Information
- Headquarters
- 3980 Premier Dr, Suite 310HIGH POINT, NC, United States 27265
- Phone
- 336-841-0300
- Fax
- 336-841-0310
Executives
- President, Chief Executive Officer, Director
- Paul Sekhri
- Chief Financial Officer
- Steven Tuch
- Executive Vice President - Corporate Development, Director
- Richard Nelson
- Chief Accounting Officer
- Barry Brown
- Chief Medical Officer
- Thomas Strack
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $77.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.55 |
EPS | $-9.79 |
Book Value | $-9.27 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
